Targeting the tumor microenvironment.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Frontiers in Bioscience

• Publication date

  2007-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2741/2327PMID 17485314PMCID PMC2841020
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumour necrosis factor-alpha as a tumour promoter.

  2006cited by this paper
• Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma.

  2006cited by this paper
• Alterations in components of the TGF-beta superfamily signaling pathways in human cancer.

  2006cited by this paper
• Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: a role for peritoneal innate immunity

  2006cited by this paper
• Macrophages: obligate partners for tumor cell migration, invasion, and metastasis.

  2006cited by this paper
• Thalidomide and hematopoietic-cell transplantation for multiple myeloma.

  2006cited by this paper
• Dichotomies in cancer research: some suggestions for a new synthesis

  2006cited by this paper
• Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts.

  2006cited by this paper
• Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?

  2006cited by this paper
• Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics

  2006cited by this paper
• Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action.

  2006cited by this paper
• Tumour necrosis factor-α as a tumour promoter

  2006cited by this paper
• Inhibition of TGFβ signaling in cancer therapy

  2006cited by this paper
• Inhibition of TGFbeta signaling in cancer therapy.

  2006cited by this paper
• Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks.

  2005cited by this paper
• Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence.

  2005cited by this paper
• Signals Which Build a Tubule

  2005cited by this paper
• Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors.

  2005cited by this paper
• Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes.

  2005cited by this paper
• Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability

  2005cited by this paper
• Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients

  2005cited by this paper
• Pharmacokinetics of His-tag recombinant human endostatin in Rhesus monkeys

  2005cited by this paper
• Loss of TGF-β type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-α-, MSP- and HGF-mediated signaling networks

  2005cited by this paper
• NF-kappaB: linking inflammation and immunity to cancer development and progression.

  2005cited by this paper
• PROSTAGLANDINS AND CANCER

  2005cited by this paper
• Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production.

  2005cited by this paper
• Smoldering and polarized inflammation in the initiation and promotion of malignant disease.

  2005cited by this paper
• Moving into the future: treatment of bone metastases and beyond.

  2005cited by this paper
• Distinct epigenetic changes in the stromal cells of breast cancers

  2005cited by this paper
• Anti-tumour activity of zoledronic acid.

  2005cited by this paper
• Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development.

  2004cited by this paper
• TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia

  2004cited by this paper
• Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues.

  2004cited by this paper
• Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors.

  2004cited by this paper
• Treatment of murine hepatocellular carcinoma using genetically modified cells to express interleukin‐12

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• TGF-Beta Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia

  2004cited by this paper
• Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors.

  2003cited by this paper
• Tumours : wounds that do not heal.

  2002cited by this paper
• The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies

  2002cited by this paper
• Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study.

  2002cited by this paper
• Stromal Effects on Mammary Gland Development and Breast Cancer

  2002cited by this paper
• Phase I study of recombinant human endostatin in patients with advanced solid tumors.

  2002cited by this paper
• Putting tumours in context

  2001cited by this paper
• Induction of embryonic primordia by implantation of organizers from a different species. 1923.

  2001cited by this paper
• Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

  2000cited by this paper
• The macrophage – a novel system to deliver gene therapy to pathological hypoxia

  2000cited by this paper
• Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis.

  2000cited by this paper
• The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis.

  1999cited by this paper
• Matrix Metalloproteinase Stromelysin-1 Triggers a Cascade of Molecular Alterations That Leads to Stable Epithelial-to-Mesenchymal Conversion and a Premalignant Phenotype in Mammary Epithelial Cells

  1997cited by this paper
• Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible?

  1997cited by this paper
• Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

  1997cited by this paper
• The tumor-promoting effect of wounding: a possible role for TGF-beta-induced stromal alterations.

  1994cited by this paper
• Aspirin Use and the Risk for Colorectal Cancer and Adenoma in Male Health Professionals

  1994cited by this paper
• Thalidomide is an inhibitor of angiogenesis.

  1994cited by this paper
• Aspirin use and reduced risk of fatal colon cancer.

  1991cited by this paper
• Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction.

  1990cited by this paper
• Fibroblast-mediated acceleration of human epithelial tumor growth in vivo.

  1990cited by this paper
• The distribution of secondary growths in cancer of the breast. 1889.

  1989cited by this paper
• Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing.

  1986cited by this paper
• Wounding and its role in RSV-mediated tumor formation.

  1985cited by this paper
• Inability of Rous sarcoma virus to cause sarcomas in the avian embryo

  1984cited by this paper
• Prostaglandins and cancer

  1982cited by this paper
• Mesenchyme-dependent morphogenesis and epithelium-specific cytodifferentiation in mouse mammary gland.

  1976cited by this paper
• Normal genetically mosaic mice produced from malignant teratocarcinoma cells.

  1975cited by this paper
• Breast Cancer: Induction of Differentiation by Embryonic Tissue

  1973cited by this paper
• Tumor angiogenesis: therapeutic implications.

  1971cited by this paper
• CYTODIFFERENTIATION AND ITS CONTROLS.

  1964cited by this paper
• THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST.

  1889cited by this paper
• Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Aromatase Activity and Expression in Breast Cancer and Benign Breast Tissue Stromal Cells*

  year unknowncited by this paper
• Carcinoma-associated Fibroblasts Direct Tumor Progression of Initiated Human Prostatic Epithelium

  year unknowncited by this paper

• Tumor-stroma proportion is associated with increased M2 macrophage abundance and predicts the resistance to immune checkpoint blockade in breast cancer

  2025cites this paper
• Nanocarriers as drug delivery system for chemotherapeutic agents: from inception to clinical implementation

  2025cites this paper
• Hypoxia-driven angiogenesis in breast cancer mechanisms and therapeutic targets: a narrative review

  2025cites this paper
• Oxygen deprivation in breast cancer: mechanisms, pathways, and implications

  2025cites this paper
• Solid tumor CAR T cells engineered with fusion proteins targeting PDL1 for localized IL-12 delivery

  2025cites this paper
• Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond

  2025cites this paper
• Unraveling the Effects of Epigallocatechin-3-gallate on Hepatocellular Carcinoma Cells: A Comparative Analysis of Monolayer vs Multicellular Tumor Spheroids

  2025cites this paper
• The influence of resolution on the predictive power of spatial heterogeneity measures as biomarkers of liver fibrosis

  2024cites this paper
• Expression of modified FcγRI enables myeloid cells to elicit robust tumor-specific cytotoxicity

  2024cites this paper
• The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review

  2024cites this paper
• Longitudinal Case-Control Study of Active and Passive Dense Mammographic Breast Tissue

  2024cites this paper
• Engineered Endosymbionts that Modulate Primary Macrophage Function and Attenuate Tumor Growth by Shifting the Tumor Microenvironment

  2024cites this paper
• Microenvironmental interference with intra-articular stem cell regeneration influences the onset and progression of arthritis

  2024cites this paper
• Tumor-Stroma Proportion to Predict Chemoresistance in Patients With Ovarian Cancer

  2024cites this paper
• Bioelectric Pharmacology of Cancer: A Systematic Review of Ion Channel Drugs Affecting the Cancer Phenotype.

  2024cites this paper
• Comparative evaluation of cytotoxic and anti-metastatic function of microbial chondroitin sulfate and animal-originated commercial chondroitin sulfate in cancer cells.

  2023cites this paper
• Nitroglycerin: a comprehensive review in cancer therapy

  2023cites this paper
• Advances in the application of neuroinflammatory molecular imaging in brain malignancies

  2023influential citation
• A Novel Gene Pair CSTF2/DPE2A Impacts Prognosis and Cell Cycle of Hepatocellular Carcinoma

  2023cites this paper
• Clinical Significance of the Stromatic Component in Ovarian Cancer: Quantity Over Quality in Outcome Prediction

  2023cites this paper
• A new insight of immunosuppressive microenvironment in osteosarcoma lung metastasis

  2023cites this paper
• Tumor microenvironment responsive metal nanoparticles in cancer immunotherapy

  2023cites this paper
• Enhanced recovery of postoperative nursing for single-port thoracoscopic surgery in lung cancer patients

  2023cites this paper
• Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR

  2023cites this paper
• Fibroblast activation protein-α expression in fibroblasts is common in the tumor microenvironment of colorectal cancer and may serve as a therapeutic target

  2023cites this paper
• Identification of a basement membrane-related genes signature to predict prognosis, immune landscape and guide therapy in gastric cancer

  2023cites this paper
• Integrated regulatory and metabolic networks of the tumor microenvironment for therapeutic target prioritization

  2023cites this paper
• Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer

  2023cites this paper
• Unlocking the potential of the tumor microenvironment for cancer therapy.

  2023cites this paper
• Curcumin-based nanomedicines: A promising avenue for brain neoplasm therapy

  2023cites this paper
• INVADEseq to identify cell-adherent or invasive bacteria and the associated host transcriptome at single-cell-level resolution

  2023cites this paper
• In situ immunomodulation of tumors with biosynthetic bacteria promote anti-tumor immunity

  2023cites this paper
• Impact of microvessel patterns and immune status in NSCLC: a non-angiogenic vasculature is an independent negative prognostic factor in lung adenocarcinoma

  2023cites this paper
• Role of 68Ga-FAPI PET/CT in Assessing Hepatobiliary Malignancies

  2023cites this paper
• The role of cancer-associated fibroblasts in bladder cancer progression

  2023cites this paper
• Cellular signaling in the hypoxic cancer microenvironment: Implications for drug resistance and therapeutic targeting.

  2023cites this paper
• Immunomodulatory activity of manganese dioxide nanoparticles: Promising for novel vaccines and immunotherapeutics

  2023cites this paper
• Bisphosphonates: From Pharmacology to Treatment

  2023cites this paper
• Pharmacological updates of nifuroxazide: Promising preclinical effects and the underlying molecular mechanisms.

  2023cites this paper
• Synthesis of thiazole-based-thiourea analogs: as anticancer, antiglycation and antioxidant agents, structure activity relationship analysis and docking study

  2023cites this paper
• The surge of HBsAb level in a HBsAg-negative ES-SCLC patient after anlotinib plus atezolizumab treatment: A case report

  2023cites this paper
• Single-nucleus RNA sequencing and deep tissue proteomics reveal distinct tumour microenvironment in stage-I and II cervical cancer

  2023cites this paper
• Advances in hyperbaric oxygen to promote immunotherapy through modulation of the tumor microenvironment

  2023cites this paper
• Fluorescent nano- and microparticles for sensing cellular microenvironment: past, present and future applications

  2023cites this paper
• As a potential predictor of pan-cancer, UBE2S is related to tumor-associated macrophage infiltration.

  2023cites this paper
• The impact of cellular elements of TME on melanoma biology and its sensitivity to EGFR and MET targeted therapy.

  2023cites this paper
• Augmenting TCR signal strength and ICOS costimulation results in metabolically fit and therapeutically potent human CAR Th17 cell therapy

  2022cites this paper
• Recent advances of metal-based nanoparticles in nucleic acid delivery for therapeutic applications

  2022cites this paper
• Nanomaterials targeting macrophages in sepsis: A promising approach for sepsis management

  2022cites this paper
• Breast Tumor Cell-Stimulated Bone Marrow-Derived Mesenchymal Stem Cells Promote the Sprouting Capacity of Endothelial Cells by Promoting VEGF Expression, Mediated in Part through HIF-1α Increase

  2022cites this paper
• Natural products targeting macrophages in tumor microenvironment are a source of potential antitumor agents.

  2022cites this paper
• Biofabrication of a tri-layered 3D-bioprinted CSC-based malignant melanoma model for personalized cancer treatment

  2022cites this paper
• Remodelling of tumour microenvironment by microwave ablation potentiates immunotherapy of AXL-specific CAR T cells against non-small cell lung cancer

  2022cites this paper
• Managing the TME to improve the efficacy of cancer therapy

  2022cites this paper
• Synthesis of boron nitride nanosheets incorporated with Pd nanoparticles for reduction of nitroaromatics

  2022cites this paper
• The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma

  2022cites this paper
• Exosomal telomerase transcripts reprogram the microRNA transcriptome profile of fibroblasts and partially contribute to CAF formation

  2022cites this paper
• STAT3 inactivation suppresses stemness properties in gastric cancer stem cells and promotes Th17 in Treg/Th17 balance.

  2022cites this paper
• Biological Characterization and Clinical Value of OAS Gene Family in Pancreatic Cancer

  2022cites this paper
• Modulation of Inflammation by Plant-Derived Nutraceuticals in Tendinitis

  2022cites this paper
• Role of STAT3 in the initiation, progression, proliferation and metastasis of breast cancer and strategies to deliver JAK and STAT3 inhibitors.

  2022cites this paper
• Tumor Stimulus-Responsive Biodegradable Diblock Copolymer Conjugates as Efficient Anti-Cancer Nanomedicines

  2022cites this paper
• Pressure increases PD-L1 expression in A549 lung adenocarcinoma cells and causes resistance to anti-ROR1 CAR T cell-mediated cytotoxicity

  2022cites this paper
• Identification and Validation of the Diagnostic Characteristic Genes of Ovarian Cancer by Bioinformatics and Machine Learning

  2022cites this paper
• A novel signature based on necroptosis-related long non-coding RNAs for predicting prognosis of patients with glioma

  2022cites this paper
• STAT3 pathway in cancers: Past, present, and future

  2022cites this paper
• Characterization of Gut Microbiota and Exploration of Potential Predictive Model for Hepatocellular Carcinoma Microvascular Invasion

  2022cites this paper
• Principles of dormancy evident in high-grade serous ovarian cancer

  2022cites this paper
• Tumor Immune Microenvironment and Immunotherapy in Brain Metastasis From Non-Small Cell Lung Cancer

  2022cites this paper
• Tim-3 Blockade Elicits Potent Anti-Multiple Myeloma Immunity of Natural Killer Cells

  2022cites this paper
• An Individualized Prognostic Signature for Clinically Predicting the Survival of Patients With Bladder Cancer

  2022cites this paper
• Inhibition of the VEGF signaling pathway attenuates tumor-associated macrophage activity in liver cancer

  2022cites this paper
• Current Status of Research on Small Extracellular Vesicles for the Diagnosis and Treatment of Urological Tumors

  2022cites this paper
• Construction of a Lactate-Related Prognostic Signature for Predicting Prognosis, Tumor Microenvironment, and Immune Response in Kidney Renal Clear Cell Carcinoma

  2022cites this paper
• Deletion of IP6K1 in mice accelerates tumor growth by dysregulating the tumor-immune microenvironment

  2022cites this paper
• Three categories of similarities between the placenta and cancer that can aid cancer treatment: Cells, the microenvironment, and metabolites

  2022cites this paper
• Detection of IL-1β, VEGF and IL-4 with their novel genetic variations in breast cancer patients

  2022cites this paper
• STAT3-regulated LncRNA LINC00160 mediates cell proliferation and cell metabolism of prostate cancer cells by repressing RCAN1 expression

  2022cites this paper
• Regulation of Tumor Invasion by the Physical Microenvironment: Lessons from Breast and Brain Cancer.

  2022cites this paper
• Discovery of 2-Amino-3-cyanothiophene Derivatives as Potent STAT3 Inhibitors for the Treatment of Osteosarcoma Growth and Metastasis.

  2022cites this paper
• Polyphenols Targeting and Influencing Cellular Signaling During Progression and Treatment of Cancer

  2021cites this paper
• Manuka honey, a unique mono-floral honey. A comprehensive review of its bioactives, metabolism, action mechanisms, and therapeutic merits

  2021cites this paper
• Identification of 4-genes model in papillary renal cell tumor microenvironment based on comprehensive analysis

  2021cites this paper
• ADAMTS9-AS1 Constrains Breast Cancer Cell Invasion and Proliferation via Sequestering miR-301b-3p

  2021cites this paper
• Seven-gene signature on tumor microenvironment for predicting the prognosis of patients with pancreatic cancer.

  2021cites this paper
• Targeting the MDSCs of Tumors In Situ With Inhibitors of the MAPK Signaling Pathway to Promote Tumor Regression

  2021cites this paper
• Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges

  2021cites this paper
• Macrophage peroxiredoxin 5 deficiency promotes lung cancer progression via ROS-dependent M2-like polarization.

  2021cites this paper
• IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma

  2021cites this paper
• LncRNAs in tumor microenvironment: the potential target for cancer treatment with natural compounds and chemical drugs.

  2021cites this paper
• CXCL10 is a Tumor Microenvironment and Immune Infiltration Related Prognostic Biomarker in Pancreatic Adenocarcinoma

  2021cites this paper
• Strategies for Dodging the Obstacles in CAR T Cell Therapy

  2021cites this paper
• Novel Insights into Epigenetic Regulation of IL6 Pathway: In Silico Perspective on Inflammation and Cancer Relationship

  2021cites this paper
• STAT3/NF‐κB signalling disruption in M2 tumour‐associated macrophages is a major target of PLGA nanocarriers/PD‐L1 antibody immunomodulatory therapy in breast cancer

  2021cites this paper
• Co nás učí nádory. Paralely v chování buněk a lidí

  2021cites this paper
• Nitric Oxide-Releasing Drug Glyceryl Trinitrate Targets JAK2/STAT3 Signaling, Migration and Invasion of Triple-Negative Breast Cancer Cells

  2021cites this paper
• Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach.

  2021cites this paper
• STAT3-mediated activation of mitochondrial pathway contributes to antitumor effect of dihydrotanshinone I in esophageal squamous cell carcinoma cells

  2021cites this paper
• (20S) Ginsenoside Rh2 Inhibits STAT3/VEGF Signaling by Targeting Annexin A2

  2021cites this paper
• Identification of LncRNA Prognostic Markers for Ovarian Cancer by Integration of Co-expression and CeRNA Network

  2021cites this paper